STUDY OF MICROBIOM OF FEMALE GENITAL ORGANS: THEORY AND PRACTICE OF THE USE OF TWO-STAGE THERAPY OF DISBIOTIC DISEASES
- Authors: Kocherovets V.I.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: No 8 (2018)
- Pages: 174-179
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248388
- ID: 248388
Cite item
Open Access
Access granted
Abstract
The literature data on the study of the microbiota of female genital organs and assess the clinical and microbiological characteristics of the probiotic strain LCR35, used in the treatment and prevention of vaginal infections were analyzed. Biotherapeutic aspects of treatment and prevention of dysbiotic conditions of vaginal microbiota have been analyzed. A comparative evaluation of the characteristics and requirements of lactobacillicontaining preparations with probiotic activity in obstetric-gynecological practice was carried out. The clinical and microbiological advantages of the original probiotic strain Lactobacillus casei rhamnosus Doderleini (LCR35) in the formulation Lactogynal in the treatment and prevention of vaginal infections were noted. The literary review of data the medical use of the culture of Lactobacillus casei rhamnosus Doderleini (LCR35) testifies to the expediency and validity of its use in the mode of two-stage therapy of the dysbiotic conditions of the vagina. Organization and conduct of additional post-registration clinical studies of medicinal product for medical use Lactogynal will strengthen the position of targeted probiotics in the complex treatment and prevention of bacterial and fungal infections of female genital organs.
Full Text
About the authors
Vladimir I. Kocherovets
I.M. Sechenov First Moscow State Medical University
Email: kftif@mail.ru
MD, professor of the Department of Pharmaceutical Technology and Pharmacology, Institute of Professional Training ll999l, Russia, Moscow, Trubetskaya str. 8, bld. 2
References
- Sirota I., Zarek S.M., Segars J.H. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin. Reprod. Med. 2014; 32(1): 35-42.
- Башмакова Н.В., Волкова Н.Ю., Гнатко Е.П., Данькова И.В., Доброхотова Ю.Э., Карахалис Л.Ю., Мальцева Л.И., Наделяева Я.Г., Потапов В.А., Серова О.Ф., Сутурина Л.В., Тарасова М.А., Татарчук Т.Ф. Пробиотик для профилактики рецидивов вульвовагинального кандидоза (результаты международного многоцентрового открытого исследования РЕВОЛАКТ). Акушерство и гинекология. 2017; 6: 136-42.
- Тапильская Т.Н., Савичева А.М., Шипицына Е.В. Применение препарата лактожиналь для коррекции нарушения микробиоценоза влагалища у беременной с наложенным швом на шейку матки: клинический случай и обзор. Журнал акушерства и женских болезней. 2016; 65(6): 89-95.
- Кира Е.Ф. Пробиотики в восстановлении микробиоценоза влагалища. Акушерство и гинекология. 2017; 5: 32-8.
- Borges S., Silva J., Teixeira P The role of Lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 2014; 289(3): 479-89.
- Versalovic J., Wilson M., eds. Therapeutic microbiology: probiotics and related strategies. ASM Press; 2008. 403p.
- Провоторова Т.В. Перспективы применения пробиотиков в лечении пациенток с бактериальным вагинозом: отдаленные результаты терапии. Российский вестник акушера-гинеколога. 2014; 14(4): 92-9.
- Senok A.C., Verstraelen H., Temmerman M., Botta G.A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 2009; (4): CD006289.
- Petrova M.I., Lievens E., Malik S., Imholz N., Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front. Physiol. 2015; 6: 81.
- Прилепская В.Н., Мирзабалаева А.К., Кира Е.Ф., Гомберг М.А., Аполихина И.А., Байрамова Г.Р. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.: Российское общество акушеров-гинекологов; 2013
- Menard J.P. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int. J. Womens Health. 2011; 3: 295-305.
- Oduyebo O.O., Anorlu R.I., Ogunsola F.T. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst. Rev. 2009; (3): CD006055.
- Кира Е.Ф. Бактериальный вагиноз. М.: МИА; 2012. 472с.
- Sgibnev A., Kremleva E. Influence of hydrogen peroxide, lactic acid, and surfactants from vaginal Lactobacilli on the antibiotic sensitivity of opportunistic bacteria. Probiotics Antimicrob. Proteins. 2017; 9(2): 131-41.
- Сгибнев А.В., Кремлева Е.А. Потенцирование активности антибиотиков метаболитами нормальной вагинальной микрофлоры. Акушерство и гинекология. 2017; 3: 108-14.
- Сгибнев А.В., Кремлева Е.А., Щетинина Ю.С., Черкасова Ю.И. Совместное применение антимикробных и пробиотических препаратов как способ повышения эффективности терапии генитальных инфекций. Акушерство и гинекология. 2018; 4: 113-8.
- Coudeyras S., Jugie G., Vermerie M., Forestier C. Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis- associated pathogens. Infect. Dis. Obstet. Gynecol. 2008; 2008: 549640.
- Atassi F., Brassart D., Grob P., Graf F., Servin A.L. Lactobacillus strains isolated from the vaginal microbiota of healthy women inhibit Prevotella bivia and Gardnerella vaginalis in coculture and cell culture. FEMS Immunol. Med. Microbiol. 2006; 48(3): 424-32.
- Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B. et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014; 11(8): 506-14.
Supplementary files
